DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.8502
Abstract: 8502Background: Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated RRMM refr... read more here.
Keywords: tolerability belantamab; safety tolerability; belantamab mafodotin; dreamm safety ... See more keywords
A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
Sign Up to like & getrecommendations! Published in 2022 at "Arquivos brasileiros de oftalmologia"
DOI: 10.5935/0004-2749.2021-0358
Abstract: A 60-year-old-male with refractory relapsed multiple myeloma presented with redness, pain, foreign body sensation, and blurred vision in both eyes that gradually increased after his third belantamab mafotodin infusion. Biomicroscopy revealed bilateral microcyst-like epithelial changes… read more here.
Keywords: belantamab; novel agent; agent myeloma; belantamab mafodotin ... See more keywords